Nadofaragene firadenovec

Nadofaragene firadenovec (pronunciation: na-doe-fa-ra-ge-ne fi-ra-de-no-vec) is a non-replicating adenovirus vector-based gene therapy used for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive, high-grade bladder cancer.

Etymology

The name "Nadofaragene firadenovec" is derived from the components of the therapy. "Nado" is short for nadofaragene, the gene that is inserted into the patient's cells. "Firadenovec" is derived from the adenovirus vector used to deliver the gene.

Mechanism of Action

Nadofaragene firadenovec works by using a non-replicating adenovirus vector to deliver the nadofaragene (a gene that codes for the protein interferon alpha 2b) into the patient's bladder cancer cells. Once inside the cells, the gene is expressed and the protein is produced, which has antiviral, antiproliferative, and immune-modulating effects.

Related Terms

• Adenovirus
• Gene Therapy
• Interferon alpha 2b
• Bacillus Calmette-Guérin
• Bladder Cancer

See Also

• List of gene therapies
• List of bladder cancer treatments

External links

• Medical encyclopedia article on Nadofaragene firadenovec
• Wikipedia's article - Nadofaragene firadenovec

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski